Baird served as co-manager on this offering
AboutAnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ:ANAB) recently completed a follow-on offering of 3,000,000 common shares at a price of $68.50 per share, generating gross proceeds of $205.5 million. AnaptysBio intends to use the net proceeds from the offering to fund its research and development efforts to further advance its pipeline of product candidates, including the ongoing and planned clinical trials for ANB020 and ANB019, and for working capital and other general corporate purposes.
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The company’s proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated and have demonstrated efficacy in an animal model of graft-versus-host disease. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation (SHM) platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio is located in San Diego, California.
CONTACT US TO LEARN MORE
- October 2017
- AnaptysBio, Inc.
- Target Location
- North America